Jiangsu Jibeier Pharmaceutical (688566) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥966.07 million, up 7.76% year-over-year; net profit attributable to shareholders was ¥261.61 million, up 19.28% year-over-year.

• Gross margin remained high at 89.46%; core product Leucogen Tablets maintained market leadership.

• R&D investment totaled ¥67.07 million, 6.94% of revenue; several innovative drugs advanced in clinical trials.

• Cash dividend of ¥2.60 per 10 shares proposed, totaling ¥51.85 million, with a payout ratio of 19.82%.

• No major quality or safety incidents; continued ESG and governance improvements.

Financial highlights

• Operating income: ¥966.07 million, up 7.76% year-over-year.

• Net profit attributable to shareholders: ¥261.61 million, up 19.28% year-over-year.

• Operating cash flow: ¥248.30 million, up 15.33% year-over-year.

• Basic and diluted EPS: ¥1.31, up 15.93% year-over-year.

• Gross margin: 89.46%; net margin: 27.09%.

Outlook and guidance

• Focus on expanding sales of Leucogen Tablets in oncology and Nitrendipine and Atenolol Tablets in cardiovascular segments.

• Accelerate NDA submission for antidepressant JJH201501 and advance clinical trials for oncology drug JJH201601.

• Continue investment in R&D and capacity expansion, with new production base and high-end formulation center under construction.

• Maintain high dividend payout and stable financial policy.